organization · Reporting owner
Logos Global Master Fund LP
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | 10% owner | November 09, 2020 | November 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viridian Therapeutics, Inc.\DE
Report date November 09, 2020 · Filed November 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,250,000 |
Reported balance
After 2020-11-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-09 · Purchase · Acquired 250,000 · Balance 6,250,000 F1: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 6,350,000 |
Reported balance
After 2020-11-09 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-11-09 · Purchase · Acquired 100,000 · Balance 6,350,000 F1: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 550,000 |
Reported balance
After 2020-11-13 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2020-11-13 · Purchase · Acquired 126,667 · Balance 550,000 F2: After giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020.
F2: After giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2020 Filed Nov 16, 2020 23:23 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseCommon Stock | 126,667 | $14.84 | $1,879,598.95 |
DisclosureSEC source: 0001567619-20-019923 · doc1.xml · nonDerivative · entry 3 Logos Global Master Fund LP · CIK 0001831371 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 F2 · shares: After giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F2 · price: After giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F2 · balance_after: After giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. Read SEC document |
| November 09, 2020 Filed Nov 16, 2020 23:23 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseCommon Stock | 100,000 | $1.16 | $116,410.00 |
DisclosureSEC source: 0001567619-20-019923 · doc1.xml · nonDerivative · entry 2 Logos Global Master Fund LP · CIK 0001831371 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,350,000 F1 · shares: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F1 · price: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F1 · balance_after: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. Read SEC document |
| November 09, 2020 Filed Nov 16, 2020 23:23 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseCommon Stock | 250,000 | $1.10 | $274,475.00 |
DisclosureSEC source: 0001567619-20-019923 · doc1.xml · nonDerivative · entry 1 Logos Global Master Fund LP · CIK 0001831371 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250,000 F1 · shares: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F1 · price: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F1 · balance_after: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.